SIGA Technologies AI Stock Analysis
Want to see SIGA full AI Analyst Report?
SIGA Technologies (SIGA) AI Stock Analysis
SIGA Technologies
(NASDAQ:SIGA)
The overall score is weighed down by a severe deterioration in current financial performance and a weak technical trend. The company is currently unprofitable and burning cash, with the stock in a clear downtrend. The primary support comes from a pristine, debt-free balance sheet and a moderately positive long-term outlook from the earnings call, driven by international contract wins and a strong cash position. However, the near-term uncertainty around U.S. procurement and delayed pipeline milestones presents significant risk.
SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $196.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 625.45K
- Price to Earnings (P/E)
- 428.1
- Beta (1Y)
- 1.20
- Revenue Growth
- -69.60%
- EPS Growth
- -99.10%
- Country
- US
- Employees
- 49
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
SIGA Technologies Business Overview & Revenue Model
Company Description
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human...
How the Company Makes Money
SIGA makes money primarily by selling TPOXX (tecovirimat) under government procurement and stockpiling programs for biodefense and emergency preparedness. A significant portion of revenue is generated through contracts and purchase orders from govern...
SIGA Technologies Earnings Call Summary
The call was generally positive, supported by completion of the BARDA 19C contract, a new Canadian agreement worth up to approximately $15 million, additional international discussions, broad TPOXX approvals and stockpiling, nine-month profitability, and a cash balance of approximately $116 million with no debt. Offsetting concerns included uncertain timing for a new U.S. procurement award, the PEP filing delay to 2028, no third-quarter product sales, third-quarter losses, and timing challenges in Europe.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
SIGA expects results from the phase I study of its pediatric formulation by year end, and expects to file its supplemental NDA for the PEP program in 2028. Under the CDND contract, valued up to approximately $15 million over the next five years, firm commitments are about $9 million over the first three years, plus up to $6 million in options; deliveries are expected to start in 2027, with an equal number of oral TPOXX courses delivered in each of the first three fiscal years, while options can be ordered and delivered at any point in time during the five-year contract. SIGA continues to believe that a new U.S. procurement contract will be awarded, although the timing of an award remains uncertain, and does not currently expect the midterm results to have any material impact on the nature or trajectory of the process beyond the typical transition period that follows any election.
SIGA Technologies Financial Statement Overview
Summary
Financial performance is deeply bifurcated. The balance sheet is a fortress with zero debt and substantial cash, but the income statement and cash flow statement show a business in steep decline, with severe margin compression, net losses, and negative free cash flow in the TTM period. The overall score reflects a rock-solid foundation being actively eroded by an unprofitable operating model.
Income Statement
25NegativeBalance Sheet
85Very PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.36M | 94.60M | 138.72M | 139.92M | 110.78M | 133.67M |
| Gross Profit | 28.29M | 64.87M | 107.43M | 122.09M | 100.34M | 117.07M |
| EBITDA | -2.17M | 30.96M | 76.61M | 88.31M | 44.65M | 89.83M |
| Net Income | 716.12K | 23.30M | 59.21M | 68.07M | 33.90M | 69.45M |
Balance Sheet | ||||||
| Total Assets | 172.65M | 219.47M | 244.34M | 254.35M | 195.04M | 214.73M |
| Cash, Cash Equivalents and Short-Term Investments | 116.38M | 154.97M | 155.40M | 150.15M | 98.79M | 103.14M |
| Total Debt | 274.61K | 595.17K | 546.82K | 564.01K | 528.17K | 466.83K |
| Total Liabilities | 9.39M | 20.65M | 28.53M | 57.49M | 24.88M | 40.41M |
| Stockholders Equity | 163.25M | 198.82M | 215.80M | 196.86M | 170.16M | 174.31M |
Cash Flow | ||||||
| Free Cash Flow | -11.57M | 43.12M | 48.72M | 94.78M | 41.61M | 11.44M |
| Operating Cash Flow | -11.53M | 43.47M | 48.76M | 94.80M | 41.61M | 11.49M |
| Investing Cash Flow | -40.54K | -355.01K | -42.45K | -21.69K | 0 | -50.62K |
| Financing Cash Flow | -44.00M | -43.55M | -43.46M | -43.42M | -45.96M | -26.20M |
SIGA Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Negative. The current price of 2.74 is below the 20-day moving average (MA) of 3.10, below the 50-day MA of 3.17, and below the 200-day MA of 4.04, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 36.11 is Neutral, neither overbought nor oversold. The STOCH value of 15.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGA.
SIGA Technologies Risk Analysis
SIGA Technologies disclosed 37 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksSIGA Technologies Peers Comparison
Overall Rating
RDY68Neutral
VTRS58Neutral
CPHI56Neutral
PRGO52Neutral
SIGA49Neutral
EBS45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | $12.18B | 41.07 | 7.37% | 0.57% | -10.52% | -55.45% | |
| 58Neutral | $23.87B | -39.28 | -4.24% | 2.31% | 4.80% | 82.97% | |
| 56Neutral | $22.29M | -0.51 | -17.14% | ― | -10.97% | 71.83% | |
| 52Neutral | $2.25B | -1.27 | -68.13% | 7.14% | -4.45% | -3289.03% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $196.88M | 428.12 | 0.42% | ― | -69.60% | -99.10% | |
| 45Neutral | $297.69M | -1.15 | -61.33% | ― | -17.72% | -456.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SIGA | Siga Technologies | 2.74 | -2.54 | -48.12% | |
| CPHI | China Pharma | 0.52 | -1.00 | -65.92% | |
| RDY | Dr. Reddy's Laboratories Ltd | 14.74 | 0.80 | 5.72% | |
| EBS | Emergent Biosolutions | 5.79 | -4.33 | -42.79% | |
| VTRS | Viatris, Inc. | 20.82 | 10.48 | 101.30% | |
| PRGO | Perrigo Company | 16.24 | 4.00 | 32.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
